Repare Therapeutics (RPTX) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Trading Symbol	RPTX
Entity Registrant Name	Repare Therapeutics Inc.
Entity Central Index Key	0001808158
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,510,708
Title of 12(b) Security	Common shares, no par value
Security Exchange Name	NASDAQ
Entity File Number	001-39335
Entity Incorporation, State or Country Code	A8
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	7171 Frederick-Banting
Entity Address, Address Line Two	Building 2
Entity Address, Address Line Three	Suite 270
Entity Address, City or Town	St-Laurent
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H4S 1Z9
City Area Code	857
Local Phone Number	412-7018
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 80,541	$ 111,268
Marketable securities	98,891	112,359
Income tax receivable	10,974	10,813
Other current receivables	3,253	4,499
Prepaid expenses	6,744	4,749
Total current assets	200,403	243,688
Property and equipment, net	2,748	4,215
Operating lease right-of-use assets	2,473	3,326
Income tax receivable	586	2,276
Other assets	179	396
TOTAL ASSETS	206,389	253,901
CURRENT LIABILITIES:
Accounts payable	10,655	2,400
Accrued expenses and other current liabilities	18,212	24,057
Operating lease liability, current portion	2,217	2,400
Deferred revenue, current portion	0	10,222
Total current liabilities	31,084	39,079
Operating lease liability, net of current portion	346	1,010
Deferred revenue, net of current portion	0	1,730
TOTAL LIABILITIES	31,430	41,819
SHAREHOLDERS’ EQUITY
Preferred shares, no par value per share; unlimited shares authorized as of September 30, 2024 and December 31, 2023 ; 0 shares issued and outstanding as of September 30, 2024, and December 31, 2023	0	0
Common shares, no par value per share; unlimited shares authorized as of September 30, 2024 and December 31, 2023; 42,510,708 and 42,176,041 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	486,674	483,350
Additional paid-in capital	77,272	61,813
Accumulated other comprehensive income	140	28
Accumulated deficit	(389,127)	(333,109)
Total shareholders’ equity	174,959	212,082
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 206,389	$ 253,901

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock par value	$ 0	$ 0
Preferred stock shares authorized	Unlimited	Unlimited
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0	$ 0
Common stock shares authorized	Unlimited	Unlimited
Common stock shares issued	42,510,708	42,176,041
Common stock shares outstanding	42,510,708	42,176,041

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Collaboration agreements	$ 0	$ 2,159	$ 53,477	$ 38,086
Operating expenses:
Research and development, net of tax credits	28,401	32,709	91,446	98,327
General and administrative	6,444	7,868	23,379	25,116
Restructuring	1,527	0	1,527	0
Total operating expenses	36,372	40,577	116,352	123,443
Loss from operations	(36,372)	(38,418)	(62,875)	(85,357)
Other income (expense), net
Realized and unrealized (loss) gain on foreign exchange	(19)	(40)	18	(137)
Interest income	2,512	3,312	8,374	10,228
Other expense	(42)	(32)	(95)	(73)
Total other income, net	2,451	3,240	8,297	10,018
Loss before income taxes	(33,921)	(35,178)	(54,578)	(75,339)
Income tax (expense) recovery	(485)	16,299	(1,440)	9,573
Net loss	(34,406)	(18,879)	(56,018)	(65,766)
Unrealized gain on available-for-sale marketable securities	274	172	112	176
Total other comprehensive income	274	172	112	176
Comprehensive loss	$ (34,132)	$ (18,707)	$ (55,906)	$ (65,590)
Net loss per share attributable to common shareholders--basic	$ (0.81)	$ (0.45)	$ (1.32)	$ (1.56)
Net loss per share attributable to common shareholders--diluted	$ (0.81)	$ (0.45)	$ (1.32)	$ (1.56)
Weighted-average common shares outstanding-basic	42,452,617	42,102,685	42,377,635	42,077,857
Weighted-average common shares outstanding-diluted	42,452,617	42,102,685	42,377,635	42,077,857

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	2020 Employee Share Purchase Plan	Common Shares	Common Shares 2020 Employee Share Purchase Plan	Additional Paid-in Capital	Additional Paid-in Capital 2020 Employee Share Purchase Plan	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2022	$ 279,517		$ 482,032		$ 37,226		$ (428)	$ (239,313)
Balance, Shares at Dec. 31, 2022			42,036,193
Share-based compensation expense	6,062				6,062
Exercise of stock options	4		$ 7		(3)
Exercise of stock options, Shares			2,000
Issuance of common shares under the 2020 Employee Share Purchase Plan		$ 409		$ 638		$ (229)
Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares				41,703
Other comprehensive income (loss)	193						193
Net income (loss)	(34,941)							(34,941)
Balance at Mar. 31, 2023	251,244		$ 482,677		43,056		(235)	(274,254)
Balance, Shares at Mar. 31, 2023			42,079,896
Share-based compensation expense	6,265				6,265
Exercise of stock options	40		$ 62		(22)
Exercise of stock options, Shares			14,050
Other comprehensive income (loss)	(189)						(189)
Net income (loss)	(11,946)							(11,946)
Balance at Jun. 30, 2023	245,414		$ 482,739		49,299		(424)	(286,200)
Balance, Shares at Jun. 30, 2023			42,093,946
Share-based compensation expense	6,377				6,377
Exercise of stock options	4		$ 6		(2)
Exercise of stock options, Shares			1,400
Issuance of common shares under the 2020 Employee Share Purchase Plan		280		$ 439		(159)
Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares				33,905
Other comprehensive income (loss)	172						172
Net income (loss)	(18,879)							(18,879)
Balance at Sep. 30, 2023	233,368		$ 483,184		55,515		(252)	(305,079)
Balance, Shares at Sep. 30, 2023			42,129,251
Balance at Dec. 31, 2023	212,082		$ 483,350		61,813		28	(333,109)
Balance, Shares at Dec. 31, 2023			42,176,041
Share-based compensation expense	6,475				6,475
Exercise of stock options	17		$ 27		(10)
Exercise of stock options, Shares			8,485
Issuance of common shares on vesting of restricted share units			$ 2,488		(2,488)
Issuance of common shares on vesting of restricted share units , Shares			200,262
Issuance of common shares under the 2020 Employee Share Purchase Plan		358		$ 510		(152)
Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares				60,618
Other comprehensive income (loss)	(141)						(141)
Net income (loss)	13,162							13,162
Balance at Mar. 31, 2024	231,953		$ 486,375		65,638		(113)	(319,947)
Balance, Shares at Mar. 31, 2024			42,445,406
Balance at Dec. 31, 2023	$ 212,082		$ 483,350		61,813		28	(333,109)
Balance, Shares at Dec. 31, 2023			42,176,041
Exercise of stock options, Shares	8,612
Balance at Sep. 30, 2024	$ 174,959		$ 486,674		77,272		140	(389,127)
Balance, Shares at Sep. 30, 2024			42,510,708
Balance at Mar. 31, 2024	231,953		$ 486,375		65,638		(113)	(319,947)
Balance, Shares at Mar. 31, 2024			42,445,406
Share-based compensation expense	6,519				6,519
Exercise of stock options, Shares			127
Other comprehensive income (loss)	(21)						(21)
Net income (loss)	(34,774)							(34,774)
Balance at Jun. 30, 2024	203,677		$ 486,375		72,157		(134)	(354,721)
Balance, Shares at Jun. 30, 2024			42,445,533
Share-based compensation expense	5,248				5,248
Issuance of common shares under the 2020 Employee Share Purchase Plan		$ 166		$ 299		$ (133)
Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares				65,175
Other comprehensive income (loss)	274						274
Net income (loss)	(34,406)							(34,406)
Balance at Sep. 30, 2024	$ 174,959		$ 486,674		$ 77,272		$ 140	$ (389,127)
Balance, Shares at Sep. 30, 2024			42,510,708

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities:
Net loss for the period	$ (56,018)	$ (65,766)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	18,242	18,704
Depreciation expense	1,467	1,445
Non-cash lease expense	1,810	1,637
Foreign exchange (gain) loss	(35)	71
Net accretion of marketable securities	(4,298)	(5,809)
Changes in operating assets and liabilities:
Prepaid expenses	(1,995)	167
Other current receivables	1,246	559
Other non-current assets	204	100
Accounts payable	8,256	4,587
Accrued expenses and other current liabilities	(5,829)	(916)
Operating lease liability, current portion	(682)	117
Income taxes	1,529	(19,291)
Operating lease liability, net of current portion	(1,066)	(1,771)
Deferred revenue	(11,952)	(32,836)
Net cash used in operating activities	(49,121)	(99,002)
Cash Flows From Investing Activities:
Purchases of property and equipment	0	(1,540)
Proceeds from maturities of marketable securities	132,015	222,000
Purchase of marketable securities	(114,133)	(174,298)
Net cash provided by investing activities	17,882	46,162
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	17	48
Proceeds from issuance of common stock under the 2020 Employee Share Purchase Plan	524	689
Net cash provided by financing activities	541	737
Effect of exchange rate fluctuations on cash held	(29)	(49)
Net Decrease In Cash And Cash Equivalents	(30,727)	(52,152)
Cash and cash equivalents at beginning of period	111,268	159,521
Cash and cash equivalents at end of period	80,541	107,369
Supplemental Disclosure Of Cash Flow Information:
Property and equipment purchases incurred but not yet paid	0	399
Right-of-use asset obtained in exchange for new operating lease liability	$ 957	$ 149

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (34,406)	$ (18,879)	$ (56,018)	$ (65,766)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Repare Therapeutics Inc. (“Repare” or the “Company”) is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company is governed by the Business Corporations Act (Québec) . The Company’s common shares are listed on the Nasdaq Global Select Market under the ticker symbol “RPTX”.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s consolidated financial position as of September 30, 2024, the consolidated results of its operations for the three and nine months ended September 30, 2024 and 2023, its statements of shareholders’ equity for the three and nine months ended September 30, 2024 and 2023 and its consolidated cash flows for the nine months ended September 30, 2024 and 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2024 (the “Annual Report”). The condensed consolidated balance sheet data as of December 31, 2023 presented for comparative purposes was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results to be expected for the full year or for any other subsequent interim period. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023 included in the Annual Report. There have been no changes to the Company's significant accounting policies since the date of the audited consolidated financial statements for the year ended December 31, 2023 included in the Annual Report. Principles of Consolidation These unaudited condensed consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (“Repare USA”), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation. Smaller Reporting Company Repare qualified as a “smaller reporting company” under the Exchange Act as of June 30, 2024 because the market value of its common shares held by non-affiliates was less than $200 million as of June 30, 2024. As a smaller reporting company, Repare may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB amended the guidance in ASU 280, Segment Reporting, to require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures currently required under ASC 280. The new guidance is effective for public entities in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently assessing the impact of this amendment on its consolidated financial statements. In December 2023, the FASB amended the guidance in ASU 740, Income Taxes, to provide disaggregated income tax disclosures on the rate reconciliation and income taxes paid. The new guidance is effective for public entities in fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently assessing the impact of this amendment on its consolidated financial statements.

Cash and Cash Equivalents and M

Cash and Cash Equivalents and Marketable Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Cash and Cash Equivalents and Marketable Securities	3. Cash and Cash Equivalents and Marketable Securities Cash and cash equivalents and marketable securities were comprised of the following: Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) As of September 30, 2024 Cash and cash equivalents: Cash $ 47,586 $ — $ — $ 47,586 Money market funds 29,970 — — 29,970 Commercial paper 2,985 — — 2,985 Total cash and cash equivalents: $ 80,541 $ — $ — $ 80,541 Marketable securities: Commercial paper $ 77,473 $ 102 $ — $ 77,575 Corporate debt securities 21,278 38 — 21,316 Total marketable securities $ 98,751 $ 140 $ — $ 98,891 As of December 31, 2023 Cash and cash equivalents: Cash $ 44,462 $ — $ — $ 44,462 Money market funds 36,991 — — 36,991 Commercial paper 29,811 4 — 29,815 Total cash and cash equivalents: $ 111,264 $ 4 $ — $ 111,268 Marketable securities: U.S. Treasury and government-sponsored $ 22,434 $ — $ ( 25 ) $ 22,409 Commercial paper 89,901 60 ( 11 ) 89,950 Total marketable securities $ 112,335 $ 60 $ ( 36 ) $ 112,359 Interest receivable was $ 0.3 million and $ 0.4 million as of September 30, 2024 and December 31, 2023, respectively, and is included in other current receivables. The Company held available-for-sale marketable securities with an aggregate fair value of nil and $ 58.6 million in an immaterial, unrealized loss position as of September 30, 2024 and December 31, 2023, respectively, as shown in the table above. These marketable securities have been in an unrealized gain and loss position for less than twelve months. The unrealized losses as of December 31, 2023, were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity . The Company does not intend to sell these securities and it is more likely than not that it will hold these investments for a period of time sufficient to recover the amortized cost. As a result, the Company did no t record an allowance for credit losses or other impairment charges for its marketable securities for the nine months ended September 30, 2024 and 2023. The Company recognized a net unrealized gain of $ 0.3 million and $ 0.2 million in other comprehensive income in the three months ended September 30, 2024 and 2023, respectively, and a net unrealized gain of $ 0.1 million and $ 0.2 million in the nine months ended September 30, 2024 and 2023, respectively, in relation to its cash and cash equivalents and marketable securities. The maturities of the Company’s marketable securities as of September 30, 2024 and December 31, 2023 are less than one year.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 – Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Description Financial Assets Level 1 Level 2 Level 3 (in thousands) As of September 30, 2024 Assets Cash equivalents: Money market funds $ 29,970 $ 29,970 $ — $ — Commercial paper 2,985 — 2,985 — Total cash equivalents 32,955 29,970 2,985 — Marketable securities: Commercial paper 77,575 — 77,575 — Corporate debt securities 21,316 — 21,316 — Total marketable securities 98,891 — 98,891 — Total financial assets $ 131,846 $ 29,970 $ 101,876 $ — As of December 31, 2023 Assets Cash equivalents: Money market funds $ 36,991 $ 36,991 $ — $ — Commercial paper 29,815 — 29,815 — Total cash equivalents 66,806 36,991 29,815 — Marketable securities: U.S. Treasury and government-sponsored enterprises 22,409 — 22,409 — Commercial paper 89,950 — 89,950 — Total marketable securities 112,359 — 112,359 — Total financial assets $ 179,165 $ 36,991 $ 142,174 $ — When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure the fair value. In determining the fair values at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data. During the nine months ended September 30, 2024 , there were no transfers between fair value measure levels.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: As of As of (in thousands) Accrued research and development expense $ 12,289 $ 16,251 Accrued compensation and benefits 4,991 6,981 Accrued professional services 402 631 Accrued restructuring expenses 476 — Other 54 194 Total accrued expenses and other current liabilities $ 18,212 $ 24,057

Restructuring Expenses

Restructuring Expenses	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Expenses	6. Restructuring Expenses In August 2024, the Company announced a strategic reprioritization of the Company's research and development activities to focus its efforts on the advancement of its portfolio of clinical-stage oncology programs. As part of this strategic refocus, the Company reduced its overall workforce by approximately 25 %, with a majority of the headcount reductions from the Company’s preclinical group. For the three and nine months ended September 30, 2024, the Company incurred approximately $ 1.5 million in costs as part of this strategic refocus, comprised primarily of severance and termination benefits.

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangements	7. Collaborative Arrangements Debiopharm Clinical Study and Collaboration Agreement In January 2024, the Company entered into a clinical study and collaboration agreement with Debiopharm International S.A. (“Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company, with the aim to explore the synergy between the Company’s compound, lunresertib, and Debiopharm’s compound, Debio 0123, a WEE1 inhibitor (the “Debio Collaboration Agreement”). The Company and Debiopharm are collaborating on the development of a combination therapy, with the Company sponsoring the global study, and will share all costs equally. The Company and Debiopharm are each supplying their respective drugs and retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies. The activities associated with the Debio Collaboration Agreement are coordinated by a joint steering committee, which is comprised of an equal number of representatives from the Company and Debiopharm. Based on the terms of the Debio Collaboration Agreement, the Company concluded that the Debio Collaboration Agreement meets the requirements of a collaboration within the guidance of ASC 808, Collaborative Arrangements, as both parties are active participants in the combination trial and are exposed to significant risks and rewards depending on the success of the combination trial. Accordingly, the net costs associated with the co-development are expensed as incurred and recognized within research and development expenses in the condensed consolidated statement of operations and comprehensive loss. During the three and nine months ended September 30, 2024, the Company recognized $ 0.8 million and $ 2.1 million , respectively, in net research and development costs with regards to the Debiopharm portion of the 50/50 cost sharing terms in the Debio Collaboration Agreement, and recorded a receivable from Debiopharm of $ 0.3 million as of September 30, 2024 in other current receivables.

Revenue recognition from Collab

Revenue recognition from Collaboration and License Agreements	9 Months Ended
	Sep. 30, 2024
Revenue Recognition [Abstract]
Revenue recognition from Collaboration and License Agreements	8. Revenue recognition from Collaboration and License Agreements The following table presents revenue from collaboration agreements: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Roche Collaboration and License Agreement $ — $ 1,659 $ 50,888 $ 11,796 Bristol-Myers Squibb Collaboration and License Agreement — 500 2,589 15,817 Ono Collaboration Agreement — — — 10,473 Total revenue $ — $ 2,159 $ 53,477 $ 38,086 The Company’s revenue recognition accounting policy, as well as additional information on the Company’s collaboration and license agreements are disclosed in the audited consolidated financial statements for the year ended December 31, 2023 included in the Annual Report. Roche Collaboration and License Agreement In June 2022, the Company entered into a collaboration and license agreement (the “Roche Agreement”) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, “Roche”) regarding the development and commercialization of the Company’s product candidate camonsertib (also known as RP-3500) and specified other Ataxia-Telangiectasia and Rad3-related protein kinase (“ATR”) inhibitors (the “Licensed Products”) which became effective July 13, 2022 (the “Effective Date”). Pursuant to the Roche Agreement, the Company granted Roche a worldwide, perpetual, exclusive, sublicensable license to develop, manufacture, and commercialize the Licensed Products, as well as a non-exclusive, sublicensable license to certain related companion diagnostics. The Company agreed to complete specified ongoing clinical trials in accordance with the development plan in the Roche Agreement, as well as ongoing investigator sponsored trials (together, the “Continuing Trials”) at the Company’s expense. Roche assumed all subsequent development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. The Company retained the right to conduct specified clinical trials (the “Repare Trials”) of camonsertib in combination with the Company’s PKMYT1 compound, lunresertib (also known as RP-6306). The Roche Agreement provided the Company, at its sole discretion, with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval was received. If the Company chose to exercise its co-development and profit share option, it would continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties. On February 7, 2024, the Company received written notice from Roche of their election to terminate the Roche Agreement following a review of Roche’s pipeline and evolving external factors. The termination became effective May 7, 2024, at which time the Company regained global development and commercialization rights for camonsertib from Roche. In February 2024, the Company received a $ 40.0 million milestone payment from Roche that was earned upon dosing of the first patient with camonsertib in Roche’s Phase 2 TAPISTRY trial in January 2024. In March 2024, the Company received a further payment of $ 4.0 million for revisions to the clinical development plan under the Roche Agreement, of which $ 2.1 million was previously recorded as a receivable at December 31, 2023. The transaction price was updated for this additional consideration received, as well as other adjustments of $ 0.5 million pursuant to the termination of the agreement. Deferred revenue pertaining to the Roche Agreement Completion of Continuing Trials (in thousands) Balance as of December 31, 2023 $ 9,463 Increase in collaboration revenue 41,425 Recognition as revenue, as the result of performance obligations satisfied ( 50,888 ) Balance as of September 30, 2024 $ — The Company recognized nil and $ 1.7 million for the three months ended September 30, 2024 and 2023, respectively, and $ 50.9 million and $ 11.8 million for the nine months ended September 30, 2024 and 2023, respectively, as revenue associated with the Roche Agreement in relation to (i) the recognition of revenue upon the $ 40.0 million milestone achievement in the first quarter of 2024, as well as (ii) the recognition of all remaining deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period. Bristol-Myers Squibb Collaboration and License Agreement In May 2020, the Company entered into a collaboration and license agreement (the “BMS Agreement”) with Bristol-Myers Squibb Company (“Bristol-Myers Squibb”), pursuant to which the Company and Bristol-Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. The Company provided Bristol-Myers Squibb access to a selected number of its existing screening campaigns and novel campaigns. The Company was responsible for carrying out early-stage research activities directed to identifying potential targets for potential licensing by Bristol-Myers Squibb, in accordance with a mutually agreed upon research plan, and was solely responsible for such costs. The collaboration consisted of programs directed to both druggable targets and to targets commonly considered undruggable to traditional small molecule approaches. Upon Bristol-Myers Squibb’s election to exercise its option to obtain exclusive worldwide licenses for the subsequent development, manufacturing and commercialization of a program, Bristol-Myers Squibb will then be solely responsible for all such worldwide activities and costs. Although the collaboration term expired in November 2023 , the BMS Agreement will not expire until, on a licensed product-by-licensed product and country-by-country basis, the expiration of the applicable royalty term and in its entirety upon expiration of the last royalty term. Either party may terminate earlier upon an uncured material breach of the agreement by the other party, or the insolvency of the other party. Additionally, Bristol-Myers Squibb may terminate the BMS Agreement for any or no reason on a program-by-program basis upon specified written notice. The Company is entitled to receive up to $ 301.0 million in total milestones on a program-by-program basis, consisting of $ 176.0 million in the aggregate for certain specified research, development and regulatory milestones and $ 125.0 million in the aggregate for certain specified commercial milestones. The Company is further entitled to a tiered percentage royalty on annual net sales ranging from high-single digits to low-double digits, subject to certain specified reductions. Deferred revenue pertaining to the BMS Agreement Options to license undruggable targets (in thousands) Balance as of December 31, 2023 $ 2,489 Increase in collaboration revenue 100 Recognition as revenue, as the result of performance obligations satisfied ( 2,589 ) Balance as of September 30, 2024 $ — In March 2024, Bristol-Myers Squibb exercised its one remaining option for an undruggable target. As a result, the Company recognized $ 2.6 million as revenue related to undruggable targets, including the option fee payment of $ 0.1 million. Ono Collaboration Agreement In January 2019, the Company entered into a research services, license and collaboration agreement, (the “Ono Agreement”), with Ono Pharmaceutical Company Ltd., or (“Ono”), pursuant to which the Company and Ono agreed to collaborate in the research of potential product candidates targeting Polθ and the development of the Company’s small molecule Polθ inhibitor program. In June 2023, the Company and Ono determined not to further extend the term of the Ono Agreement. As a result, no product candidate would be licensed to Ono pursuant to the terms of the Ono Agreement. The Company recognized approximately $ 10.5 million as revenue for the nine months ended September 30, 2023 with regards to the performance obligation under the Ono Agreement. The Company did no t recognize any revenue pursuant to the Ono Agreement during the three and nine months ended September 30, 2024 .

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	9. Leases The Company has historically entered into lease arrangements for its facilities. As of September 30, 2024 , the Company had four operating leases with required future minimum payments. The Company’s leases generally do not include termination or purchase options. In August 2024, the Company entered into a lease renewal agreement for office space in Cambridge, Massachusetts, for a twelve-month term ending in January 2026 , which will result in additional minimum lease payments of $ 1.1 million over the twelve-month extended lease term . The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. During the third quarter of 2024, the Company determined the carrying value of the right-of-use asset related to the office and laboratory space in Montréal, Québec was no longer recoverable and wrote the balance down to its estimated fair value of nil. The resulting impairment loss of $ 0.1 million is reflected within research and development expenses. Operating Leases The following tables contain a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Operating Leases - Lease Costs Operating lease costs $ 708 $ 593 $ 1,895 $ 1,779 Short-term lease costs 26 39 60 86 Variable lease costs 77 86 245 186 Total lease costs $ 811 $ 718 $ 2,200 $ 2,051 Nine Months Ended 2024 2023 (in thousands, except as specified otherwise) Other Operating Lease Information Operating cash flows used for operating leases $ 1,837 $ 1,799 Right-of-use assets obtained in exchange for new operating lease liability $ 957 $ 149 Weighted-average remaining lease term (in years) 1.13 1.70 Weighted-average discount rate 7.7 % 4.1 %

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	10. Share-Based Compensation 2020 Employee Share Purchase Plan In June 2020, the Company’s board of directors adopted, and the Company’s shareholders approved the 2020 Employee Share Purchase Plan (“ESPP”). The number of shares reserved and available for issuance under the ESPP will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 31, 2030, by the lesser of (1) 1.0 % of the total number of common shares outstanding on December 31 of the preceding calendar year, (2) 3,300,000 common shares, or (3) such smaller number of common shares as the Company’s board of directors may designate. The Company issued 125,793 common shares under the ESPP for the nine months ended September 30, 2024, at a weighted-average price per share of $ 4.17 , for aggregate proceeds of $ 0.5 million . As of September 30, 2024, the number of common shares that may be issued under the ESPP is 1,707,393 . 2020 Equity Incentive Plan In June 2020, the Company’s board of directors adopted, and the Company’s shareholders approved the 2020 Equity Incentive Plan (the ”2020 Plan”). The 2020 Plan became effective on the effective date of the Company's initial public offering (the "IPO"), at which time the Company ceased making awards under the Option Plan. The 2020 Plan allows the Company’s compensation committee to make equity-based and cash-based incentive awards to the Company’s officers, employees, directors and consultants including but not limited to stock options and restricted share units. The aggregate number of common shares reserved and available for issuance under the 2020 Plan has automatically increased on January 1 of each year beginning on January 1, 2021 and will continue to increase on January 1 of each year through and including January 1, 2030, by 5 % of the outstanding number of common shares on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s board of directors. As of September 30, 2024 , the number of common shares reserved for issuance under the 2020 Plan is 12,144,106 . Inducement Plan In April 2024, the Company’s board of directors approved the adoption of the 2024 Inducement Plan (the “Inducement Plan”), to be used exclusively for grants of awards to individuals who were not previously employees or directors (or following a bona fide period of non-employment) as a material inducement to such individuals’ entry into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). The terms and conditions of the Inducement Plan are substantially similar to those of the 2020 Plan. 350,000 common shares have been reserved for issuance under the Inducement Plan. Stock Options The following table summarizes the Company’s stock options activity: Number of Weighted Outstanding, January 1, 2024 10,097,771 $ 13.77 Granted 1,621,082 $ 6.48 Exercised ( 8,612 ) $ 1.99 Cancelled or forfeited ( 702,966 ) $ 12.98 Outstanding, September 30, 2024 11,007,275 $ 12.76 The fair value of stock options, and the assumptions used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted average basis: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Fair value of stock options $ — $ 7.77 $ 4.72 $ 8.31 Risk-free interest rate — 4.36 % 4.21 % 3.71 % Expected terms (in years) — 6.08 5.97 6.01 Expected volatility — 81.73 % 83.08 % 81.49 % Expected dividend yield — 0.00 % 0.00 % 0.00 % Restricted Share Units The following table summarizes the Company’s restricted share unit activity: Number of Weighted Outstanding, January 1, 2024 603,685 $ 12.42 Awarded 527,273 $ 6.95 Vested and released ( 200,262 ) $ 12.42 Forfeited ( 126,015 ) $ 10.23 Outstanding, September 30, 2024 804,681 $ 9.18 The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common shares on that same date. Share-Based Compensation Share-based compensation expense for all awards was allocated as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Research and development $ 3,231 $ 3,339 $ 10,344 $ 9,887 General and administrative 2,017 3,038 7,898 8,817 Total share-based compensation expense $ 5,248 $ 6,377 $ 18,242 $ 18,704 Share-based compensation expense by type of award was as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Stock options $ 4,573 $ 5,678 $ 15,863 $ 16,776 Restricted share units 689 625 2,201 1,670 ESPP ( 14 ) 74 178 258 Total share-based compensation expense $ 5,248 $ 6,377 $ 18,242 $ 18,704 As of September 30, 2024, there was $ 24.6 million and $ 5.4 million of unrecognized share-based compensation expense to be recognized over a weighted average period of 1.1 years and 2.0 years related to unvested stock options and unvested restricted share units, respectively.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss per Share	11. Net Loss per Share The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands, except share and per share amounts) Numerator: Net loss $ ( 34,406 ) $ ( 18,879 ) $ ( 56,018 ) $ ( 65,766 ) Denominator: Weighted-average common shares outstanding — basic and 42,452,617 42,102,685 42,377,635 42,077,857 Net loss per share - basic and diluted $ ( 0.81 ) $ ( 0.45 ) $ ( 1.32 ) $ ( 1.56 ) The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Options to purchase common shares 11,007,275 10,087,591 11,007,275 10,087,591 Restricted share units 804,681 604,960 804,681 604,960 Estimated shares issuable under the ESPP 82,118 55,327 82,118 55,327

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	12. Subsequent Event Sales Agreement On November 7, 2024, the Company entered into a Common Shares Sales Agreement, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell, from time to time at prevailing market prices, common shares, or the ATM Shares. The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-281298), which was declared effective by the Securities and Exchange Commission, or SEC, on August 19, 2024, up to a maximum aggregate amount of $ 100.0 million. The Company will file a prospectus supplement with the SEC on November 7, 2024 in connection with the offer and sale of the ATM Shares pursuant to the Sales Agreement. In connection with the Sales Agreement, the Company and TD Cowen terminated their prior Common Share Sales Agreement dated August 4, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s consolidated financial position as of September 30, 2024, the consolidated results of its operations for the three and nine months ended September 30, 2024 and 2023, its statements of shareholders’ equity for the three and nine months ended September 30, 2024 and 2023 and its consolidated cash flows for the nine months ended September 30, 2024 and 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2024 (the “Annual Report”). The condensed consolidated balance sheet data as of December 31, 2023 presented for comparative purposes was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results to be expected for the full year or for any other subsequent interim period. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023 included in the Annual Report. There have been no changes to the Company's significant accounting policies since the date of the audited consolidated financial statements for the year ended December 31, 2023 included in the Annual Report.
Principles of Consolidation	Principles of Consolidation These unaudited condensed consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (“Repare USA”), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.
Smaller Reporting Company	Smaller Reporting Company Repare qualified as a “smaller reporting company” under the Exchange Act as of June 30, 2024 because the market value of its common shares held by non-affiliates was less than $200 million as of June 30, 2024. As a smaller reporting company, Repare may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB amended the guidance in ASU 280, Segment Reporting, to require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures currently required under ASC 280. The new guidance is effective for public entities in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently assessing the impact of this amendment on its consolidated financial statements. In December 2023, the FASB amended the guidance in ASU 740, Income Taxes, to provide disaggregated income tax disclosures on the rate reconciliation and income taxes paid. The new guidance is effective for public entities in fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently assessing the impact of this amendment on its consolidated financial statements.

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of Cash and Cash Equivalents and Marketable Securities	Cash and cash equivalents and marketable securities were comprised of the following: Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) As of September 30, 2024 Cash and cash equivalents: Cash $ 47,586 $ — $ — $ 47,586 Money market funds 29,970 — — 29,970 Commercial paper 2,985 — — 2,985 Total cash and cash equivalents: $ 80,541 $ — $ — $ 80,541 Marketable securities: Commercial paper $ 77,473 $ 102 $ — $ 77,575 Corporate debt securities 21,278 38 — 21,316 Total marketable securities $ 98,751 $ 140 $ — $ 98,891 As of December 31, 2023 Cash and cash equivalents: Cash $ 44,462 $ — $ — $ 44,462 Money market funds 36,991 — — 36,991 Commercial paper 29,811 4 — 29,815 Total cash and cash equivalents: $ 111,264 $ 4 $ — $ 111,268 Marketable securities: U.S. Treasury and government-sponsored $ 22,434 $ — $ ( 25 ) $ 22,409 Commercial paper 89,901 60 ( 11 ) 89,950 Total marketable securities $ 112,335 $ 60 $ ( 36 ) $ 112,359

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Description Financial Assets Level 1 Level 2 Level 3 (in thousands) As of September 30, 2024 Assets Cash equivalents: Money market funds $ 29,970 $ 29,970 $ — $ — Commercial paper 2,985 — 2,985 — Total cash equivalents 32,955 29,970 2,985 — Marketable securities: Commercial paper 77,575 — 77,575 — Corporate debt securities 21,316 — 21,316 — Total marketable securities 98,891 — 98,891 — Total financial assets $ 131,846 $ 29,970 $ 101,876 $ — As of December 31, 2023 Assets Cash equivalents: Money market funds $ 36,991 $ 36,991 $ — $ — Commercial paper 29,815 — 29,815 — Total cash equivalents 66,806 36,991 29,815 — Marketable securities: U.S. Treasury and government-sponsored enterprises 22,409 — 22,409 — Commercial paper 89,950 — 89,950 — Total marketable securities 112,359 — 112,359 — Total financial assets $ 179,165 $ 36,991 $ 142,174 $ —

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: As of As of (in thousands) Accrued research and development expense $ 12,289 $ 16,251 Accrued compensation and benefits 4,991 6,981 Accrued professional services 402 631 Accrued restructuring expenses 476 — Other 54 194 Total accrued expenses and other current liabilities $ 18,212 $ 24,057

Revenue recognition from Coll_2

Revenue recognition from Collaboration and License Agreements (Tables)	9 Months Ended
	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Schedule of Revenue From Collaboration Agreements	The following table presents revenue from collaboration agreements: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Roche Collaboration and License Agreement $ — $ 1,659 $ 50,888 $ 11,796 Bristol-Myers Squibb Collaboration and License Agreement — 500 2,589 15,817 Ono Collaboration Agreement — — — 10,473 Total revenue $ — $ 2,159 $ 53,477 $ 38,086
Roche
Disaggregation of Revenue [Line Items]
Schedule of Deferred Revenue	Deferred revenue pertaining to the Roche Agreement Completion of Continuing Trials (in thousands) Balance as of December 31, 2023 $ 9,463 Increase in collaboration revenue 41,425 Recognition as revenue, as the result of performance obligations satisfied ( 50,888 ) Balance as of September 30, 2024 $ —
Bristol-Myers Squibb Company
Disaggregation of Revenue [Line Items]
Schedule of Deferred Revenue	Deferred revenue pertaining to the BMS Agreement Options to license undruggable targets (in thousands) Balance as of December 31, 2023 $ 2,489 Increase in collaboration revenue 100 Recognition as revenue, as the result of performance obligations satisfied ( 2,589 ) Balance as of September 30, 2024 $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Summary of Lease Costs	The following tables contain a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Operating Leases - Lease Costs Operating lease costs $ 708 $ 593 $ 1,895 $ 1,779 Short-term lease costs 26 39 60 86 Variable lease costs 77 86 245 186 Total lease costs $ 811 $ 718 $ 2,200 $ 2,051
Summary of Other Operating Lease Information	Nine Months Ended 2024 2023 (in thousands, except as specified otherwise) Other Operating Lease Information Operating cash flows used for operating leases $ 1,837 $ 1,799 Right-of-use assets obtained in exchange for new operating lease liability $ 957 $ 149 Weighted-average remaining lease term (in years) 1.13 1.70 Weighted-average discount rate 7.7 % 4.1 %

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share Option Activity	The following table summarizes the Company’s stock options activity: Number of Weighted Outstanding, January 1, 2024 10,097,771 $ 13.77 Granted 1,621,082 $ 6.48 Exercised ( 8,612 ) $ 1.99 Cancelled or forfeited ( 702,966 ) $ 12.98 Outstanding, September 30, 2024 11,007,275 $ 12.76
Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model	The fair value of stock options, and the assumptions used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted average basis: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Fair value of stock options $ — $ 7.77 $ 4.72 $ 8.31 Risk-free interest rate — 4.36 % 4.21 % 3.71 % Expected terms (in years) — 6.08 5.97 6.01 Expected volatility — 81.73 % 83.08 % 81.49 % Expected dividend yield — 0.00 % 0.00 % 0.00 %
Summary of Total Outstanding Restricted Stock Units	The following table summarizes the Company’s restricted share unit activity: Number of Weighted Outstanding, January 1, 2024 603,685 $ 12.42 Awarded 527,273 $ 6.95 Vested and released ( 200,262 ) $ 12.42 Forfeited ( 126,015 ) $ 10.23 Outstanding, September 30, 2024 804,681 $ 9.18
Schedule of Share-based Compensation Expense	Share-based compensation expense for all awards was allocated as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Research and development $ 3,231 $ 3,339 $ 10,344 $ 9,887 General and administrative 2,017 3,038 7,898 8,817 Total share-based compensation expense $ 5,248 $ 6,377 $ 18,242 $ 18,704 Share-based compensation expense by type of award was as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands) Stock options $ 4,573 $ 5,678 $ 15,863 $ 16,776 Restricted share units 689 625 2,201 1,670 ESPP ( 14 ) 74 178 258 Total share-based compensation expense $ 5,248 $ 6,377 $ 18,242 $ 18,704

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Loss Per Share Attributable To Common Shareholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (in thousands, except share and per share amounts) Numerator: Net loss $ ( 34,406 ) $ ( 18,879 ) $ ( 56,018 ) $ ( 65,766 ) Denominator: Weighted-average common shares outstanding — basic and 42,452,617 42,102,685 42,377,635 42,077,857 Net loss per share - basic and diluted $ ( 0.81 ) $ ( 0.45 ) $ ( 1.32 ) $ ( 1.56 )
Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Options to purchase common shares 11,007,275 10,087,591 11,007,275 10,087,591 Restricted share units 804,681 604,960 804,681 604,960 Estimated shares issuable under the ESPP 82,118 55,327 82,118 55,327

Cash and Cash Equivalents and_3

Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Cash and cash equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 80,541	$ 111,264
Unrealized Gains	0	4
Unrealized Losses	0	0
Fair Value	80,541	111,268
Money market funds | Cash and cash equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	29,970	36,991
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	29,970	36,991
Marketable securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	98,751	112,335
Unrealized Gains	140	60
Unrealized Losses	0	(36)
Fair Value	98,891	112,359
Commercial paper | Cash and cash equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,985	29,811
Unrealized Gains	0	4
Unrealized Losses	0	0
Fair Value	2,985	29,815
Commercial paper | Marketable securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	77,473	89,901
Unrealized Gains	102	60
Unrealized Losses	0	(11)
Fair Value	77,575	89,950
Corporate debt securities | Marketable securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	21,278
Unrealized Gains	38
Unrealized Losses	0
Fair Value	21,316
U.S. Treasury and government-sponsored enterprises | Marketable securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		22,434
Unrealized Gains		0
Unrealized Losses		(25)
Fair Value		22,409
Cash | Cash and cash equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	47,586	44,462
Fair Value	$ 47,586	$ 44,462

Cash and Cash Equivalents and_4

Cash and Cash Equivalents and Marketable Securities - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Interest receivable	$ 300,000		$ 300,000		$ 400,000
Debt securities unrealized loss position	0		0		$ 58,600,000
OCI, unrealized gain on available for sale marketable securities	$ 274,000	$ 172,000	112,000	$ 176,000
Allowance for credit losses or other impairment charges			$ 0	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets
Cash equivalents	$ 32,955	$ 66,806
Marketable securities	98,891	112,359
Total financial assets	131,846	179,165
Level 1
Assets
Cash equivalents	29,970	36,991
Marketable securities	0	0
Total financial assets	29,970	36,991
Level 2
Assets
Cash equivalents	2,985	29,815
Marketable securities	98,891	112,359
Total financial assets	101,876	142,174
Corporate debt securities
Assets
Marketable securities	21,316
Corporate debt securities | Level 2
Assets
Marketable securities	21,316
U.S. Treasury and government-sponsored enterprises
Assets
Marketable securities		22,409
U.S. Treasury and government-sponsored enterprises | Level 2
Assets
Marketable securities		22,409
Money market funds
Assets
Total financial assets	29,970	36,991
Money market funds | Level 1
Assets
Total financial assets	29,970	36,991
Commercial paper
Assets
Cash equivalents	2,985	29,815
Marketable securities	77,575	89,950
Commercial paper | Level 2
Assets
Cash equivalents	2,985	29,815
Marketable securities	$ 77,575	$ 89,950

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Sep. 30, 2024 USD ($)
Fair Value Disclosures [Abstract]
Fair value, assets, transfers between levels	$ 0

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued research and development expense	$ 12,289	$ 16,251
Accrued compensation and benefits	4,991	6,981
Accrued professional services	402	631
Accrued restructuring expenses	476	0
Other	54	194
Total accrued expenses and other current liabilities	$ 18,212	$ 24,057

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2024	Sep. 30, 2024	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Percentage of overall reduction in workforce	25%
Restructuring costs		$ 1.5	$ 1.5

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current receivables	$ 3,253	$ 3,253	$ 4,499
Debiopharm
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement of research and development cost contract	800	2,100
Other current receivables	$ 300	$ 300

Revenue recognition from Coll_3

Revenue recognition from Collaboration and License Agreements - Schedule of Revenue From Collaboration Agreements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Collaboration agreements	$ 0	$ 2,159	$ 53,477	$ 38,086
Roche
Disaggregation of Revenue [Line Items]
Collaboration agreements	0	1,659	50,888	11,796
Bristol-Myers Squibb Company
Disaggregation of Revenue [Line Items]
Collaboration agreements	0	500	2,589	15,817
Ono Collaboration Agreement
Disaggregation of Revenue [Line Items]
Collaboration agreements	$ 0	$ 0	$ 0	$ 10,473

Revenue recognition from Coll_4

Revenue recognition from Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2024	May 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Feb. 29, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			$ 0	$ 2,159	$ 53,477	$ 38,086
Roche
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			0	1,659	50,888	11,796
Roche | Completion of Continuing Trials [Member]
Disaggregation of Revenue [Line Items]
Deferred revenue			0		0			$ 9,463
Roche | Collaboration and License Agreement
Disaggregation of Revenue [Line Items]
Collaboration payable	$ 500
Milestones payments received							$ 40,000
Deferred revenue recognized			0	1,700	50,900	11,800
Roche | Collaboration and License Agreement | Third Additional Clinical Development Plan
Disaggregation of Revenue [Line Items]
Collaboration revenue received	4,000
Collaboration revenue receivable earned								$ 2,100
Bristol-Myers Squibb Company
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			0	500	2,589	15,817
Bristol-Myers Squibb Company | Collaboration and License Agreement
Disaggregation of Revenue [Line Items]
Collaboration term expiration date		Nov. 30, 2023
Bristol-Myers Squibb Company | Collaboration and License Agreement | Undruggable targets
Disaggregation of Revenue [Line Items]
Deferred revenue recognized	2,600
Option fee payment	$ 100
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		$ 301,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		176,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Commercial Milestones
Disaggregation of Revenue [Line Items]
Milestone payments entitled to be received		$ 125,000
Ono Collaboration Agreement
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreements			$ 0	$ 0	$ 0	$ 10,473

Revenue recognition from Coll_5

Revenue recognition from Collaboration and License Agreements - Schedule of Deferred Revenue (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Roche | Completion of continuing trials
Disaggregation of Revenue [Line Items]
Balance, Beginning	$ 9,463
Increase in collaboration revenue	41,425
Recognition as revenue, as the result of performance obligations satisfied	(50,888)
Balance, Ending	0
Bristol-Myers Squibb Company | Options to License Undruggable Targets
Disaggregation of Revenue [Line Items]
Balance, Beginning	2,489
Increase in collaboration revenue	100
Recognition as revenue, as the result of performance obligations satisfied	(2,589)
Balance, Ending	$ 0

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) Lease	Sep. 30, 2023 USD ($)
Lessee Lease Description [Line Items]
Number of operating leases | Lease			4
Lessee, operating lease, existence of option to terminate			false
Operating minimum lease payments			$ 1,837	$ 1,799
Cambridge, Massachusetts | Office Space
Lessee Lease Description [Line Items]
Operating minimum lease payments	$ 1,100
Operating lease, option to extend, description	over the twelve-month extended lease term
Minimum lease term	12 months
Operating lease, expiration month and year	2026-01
Research and Development | Montreal, Quebec | Office and Laboratory Space
Lessee Lease Description [Line Items]
Operating lease impairment loss		$ 100	$ 100

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lease Costs
Operating lease costs	$ 708	$ 593	$ 1,895	$ 1,779
Short-term lease costs	26	39	60	86
Variable lease costs	77	86	245	186
Total lease costs	$ 811	$ 718	$ 2,200	$ 2,051

Leases - Summary of Other Opera

Leases - Summary of Other Operating Lease Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Operating cash flows used for operating leases	$ 1,837	$ 1,799
Right-of-use asset obtained in exchange for new operating lease liability	$ 957	$ 149
Weighted-average remaining lease term (in years)	1 year 1 month 17 days	1 year 8 months 12 days
Weighted-average discount rate	7.70%	4.10%

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended					9 Months Ended
	Jun. 30, 2020	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Apr. 30, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares issued							42,510,708			42,176,041
Weighted average exercise price of stock options granted							$ 6.48
Number of options exercised							8,612
Stock options granted to employees							1,621,082
Options, weighted-average exercise price							$ 1.99
Aggregate proceeds from exercise of options							$ 17	$ 48
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense related to unvested restricted share units							$ 5,400
Unrecognized share-based compensation expense related to unvested stock options, weighted average period							2 years
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense related to unvested stock options							$ 24,600
Unrecognized share-based compensation expense related to unvested stock options, weighted average period							1 year 1 month 6 days
Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance									350,000
Common Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options exercised		127	8,485	1,400	14,050	2,000
2020 Employee Share Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance							1,707,393
Annual increases in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year	1%
Annual increases in number of shares available for issuance maximum number of common stock issued	3,300,000
Common stock shares issued							125,793
Shares issued, price per share							$ 4.17
Cash received from purchases under ESPP							$ 500
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance							12,144,106
Annual increases in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year	5%

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share Option Activity (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of shares, Outstanding at beginning of period | shares	10,097,771
Number of shares, Granted | shares	1,621,082
Number of shares, Exercised | shares	(8,612)
Number of shares, Cancelled or forfeited | shares	(702,966)
Number of shares, Outstanding at end of period | shares	11,007,275
Weighted average exercise price, Outstanding at beginning of period | $ / shares	$ 13.77
Weighted average exercise price of stock options granted | $ / shares	6.48
Weighted average exercise price, Exercised | $ / shares	1.99
Weighted average exercise price, Cancelled or forfeited | $ / shares	12.98
Weighted average exercise price, Outstanding at end of period | $ / shares	$ 12.76

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details) - 2020 Equity Incentive Plan - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of stock options	$ 0	$ 7.77	$ 4.72	$ 8.31
Risk-free interest rate	0%	4.36%	4.21%	3.71%
Expected terms (in years)		6 years 29 days	5 years 11 months 19 days	6 years 3 days
Expected volatility	0%	81.73%	83.08%	81.49%
Expected dividend yield	0%	0%	0%	0%

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Total Outstanding Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units, Beginning balance | shares	603,685
Restricted stock units, Awarded | shares	527,273
Restricted stock units, Vested and released | shares	(200,262)
Restricted stock units, Forfeited | shares	(126,015)
Restricted stock units, Ending balance | shares	804,681
Weighted average grant date fair value, Beginning balance | $ / shares	$ 12.42
Weighted average grant date fair value, Awarded | $ / shares	6.95
Weighted average grant date fair value, Vested and released | $ / shares	12.42
Weighted Average Grant Date Fair Value Forfeited | $ / shares	10.23
Weighted average grant date fair value, Ending balance | $ / shares	$ 9.18

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 5,248	$ 6,377	$ 18,242	$ 18,704
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	3,231	3,339	10,344	9,887
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	2,017	3,038	7,898	8,817
Employee Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	4,573	5,678	15,863	16,776
Restricted Stock Units (RSUs)
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	689	625	2,201	1,670
2020 Employee Share Purchase Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ (14)	$ 74	$ 178	$ 258

Net Loss per Share - Summary of

Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net loss	$ (34,406)	$ (18,879)	$ (56,018)	$ (65,766)
Denominator:
Weighted-average common shares outstanding-basic	42,452,617	42,102,685	42,377,635	42,077,857
Weighted-average common shares outstanding-diluted	42,452,617	42,102,685	42,377,635	42,077,857
Net loss per share basic	$ (0.81)	$ (0.45)	$ (1.32)	$ (1.56)
Net loss per share diluted	$ (0.81)	$ (0.45)	$ (1.32)	$ (1.56)

Net Loss per Share - Computatio

Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Options to Purchase Common Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	11,007,275	10,087,591	11,007,275	10,087,591
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	804,681	604,960	804,681	604,960
Estimated Shares Issuable Under the ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	82,118	55,327	82,118	55,327

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) $ in Millions	Nov. 07, 2024 USD ($)
Subsequent Event | Sales Agreement | Maximum | Common Stock
Subsequent Event [Line Items]
Maximum aggregate amount	$ 100